OR WAIT null SECS
It was a busy week for the Contemporary OB/GYN team.
This week's top articles included:
The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.
“Topical drug delivery also provides higher concentrations of the drug to the target site and has fewer side effects,” wrote the authors.
We spoke with Editorial Board member Ilana Cass, MD, about her opinion of her state's latest abortion restrictions.